Health Enhancement Products, Inc. Receives Initial Purchase Order Under the Zus Health Contract; Zus Transfers Contract Rights to Ceptazyme and Xooma Worldwide

SCOTTSDALE, AZ--(Marketwire - December 13, 2010) - Health Enhancement Products, Inc. (HEPI) (OTCBB: HEPI) announced today that it has received its first purchase order from the contract that it completed with Zus Health, LLC (Zus) for ProAlgaZyme® (PAZ™). The Company recently signed a licensing and distribution agreement with Zus for worldwide sales & marketing rights to its proprietary algal extract PAZ™. Subsequently Zus Health sold this product line to Ceptazyme, LLC. Ceptazyme has partnered with Xooma Worldwide, a direct marketing group with representatives in over 60 countries for the direct sales segment of the market.

The Company expects to deliver the initial order in February 2011. In addition, the Company will begin to receive monthly orders, which are expected to increase on a regular basis as Ceptazyme and Xooma Worldwide roll out the product to its distributors in over 60 countries.

"Monetizing PAZ™ is a tremendous step forward for HEPI. We will be starting the year off recognizing meaningful revenue for the first time in the Company's history. The revenue stream will give us greater flexibility to focus on the pharmaceutical side of the business," stated HEPI Executive Vice President John Gorman. Mr. Gorman concluded, "We are also working diligently with Ceptazyme to offer alternative methods of delivery for PAZ™ with all its associated benefits."

Bradley Robinson, Ceptazyme Chairman, stated, "We are excited about the strength that Xooma has brought to this partnership through its direct sales channels and for individuals to benefit from PAZ™ in the additional distribution channels that we have been preparing for the introduction of PAZ™. We look forward to building our order flow in the coming months and are encouraged by HEPI's efforts in providing additional methods to deliver PAZ™ on a mass market scale."

Ron Howell, CEO/President of Xooma Worldwide, stated, "We are pleased to initiate the launch of PAZ™ through our worldwide organization. Our initial due diligence has resonated well with our Leadership. We believe that PAZ™ will be a 'game changing' product in the market place and another contribution to our 'Changing the Health of a Generation' mission. Xooma continues to set new standards in the acquisition and distribution of break-through technologies. PAZ™ represents a unique product with measurable results in preventative health care. We are excited to enter the cardiovascular health maintenance world with a truly extraordinary product."

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of a product comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.

About Xooma Worldwide

Xooma Worldwide is a wholly owned subsidiary of The Health Network, Inc. The company specializes in the formulation, development and distribution of proprietary products. Servicing consumers through a direct marketing sales organization, the company currently markets in over 60 countries. The Health Network, Inc. began business in 1993.

About Ceptazyme, LLC

Ceptazyme, LLC specializes in manufacturing and distributing of only the highest quality nutraceuticals through worldwide distribution channels. 

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

Contact Information:

IR Contact:

David Sasso
954-990-5451